Moderna Inc (MRNA)

[axelvento]

Moderna predicts the post-pandemic market will follow that of the flu. In the U.S. alone, about half of Americans go for flu shots

Moderna's pipeline includes more than 40 programs. Today, three candidates outside the coronavirus program are in phase 3 trials -- and close to the finish line. These are vaccine candidates for respiratory syncytial virus (RSV), cytomegalovirus (CMV), and flu. Moderna aims to file for regulatory approval of the RSV candidate in the first half of this year.


The company recently reported positive data from a phase 2 trial of its personalized cancer vaccine combined with Merck's Keytruda. In fact, the U.S. Food and Drug Administration even granted the combination a breakthrough therapy designation. This is meant to accelerate the development of promising products for serious conditions.

the future looks bright, with many huge potential growth drivers right around the corner!!!!!!